Least squares (LS) mean change from baseline (95% CI) in St George's Respiratory Questionnaire (SGRQ) Total score according to previous chronic obstructive.

Slides:

Advertisements

Similar presentations

Lancet Respir Med 2013; 1: 199–209 R4.신재령 / Prof. 박명재

Advertisements

LSU Journal Club Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD WISDOM study H. Magnussen MD, et al. Nisha Loganantharaj, PGY1 April 21,

내과 R2 이지훈 N Engl J Med Sep 8.

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Use of Inhaled Corticosteroids and the Risk.

GOLD 2017 major revision: Summary of key changes

A stepwise therapeutic approach in severe uncontrolled asthmatic subjects. A stepwise therapeutic approach in severe uncontrolled asthmatic subjects. GINA:

The Role of Fixed-Dose Dual Bronchodilator Therapy in Treating COPD

Volume 153, Issue 4, Pages (April 2018)

Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to chronic obstructive pulmonary disease.

Ventilatory and cerebrovascular responses to hyperoxic hypercapnia.

Consolidated Standards of Reporting Trials (CONSORT) diagram of patients enrolled in the study. #: Two pre-screen/screen failures were erroneously randomised,

Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.

Relationship between the change in a) ventilatory and b) cerebrovascular responses in older healthy subjects (Older) and chronic obstructive pulmonary.

Change from baseline in trough forced expiratory volume in 1 s (FEV1) (per-protocol population). Change from baseline in trough forced expiratory volume.

Prevalence of true-positive, false-negative and false-positive cases of chronic obstructive pulmonary disease identified with the fixed-limit Global Initiative.

A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,

Survival without tracheostomy

Volume 152, Issue 6, Pages (December 2017)

Influence of do-not-resuscitate (DNR) order specification on overall survival in chronic obstructive pulmonary disease (COPD) patients (log rank test p

Distribution of lower extremity artery disease (LEAD) Fontaine stages over the combined chronic obstructive pulmonary disease (COPD) Global Initiative.

Least squares (LS) mean change from baseline (95% CI) in St George's Respiratory Questionnaire (SGRQ) Total score according to exacerbation history (intent-to-treat.

Effects of reslizumab on asthma quality of life questionnaire (AQLQ) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of reslizumab.

Venn diagram showing the overlap between the various chronic obstructive pulmonary disease (COPD) diagnoses: self-reported physician-diagnosed, fixed ratio.

Examination of the prevalence of asthma exacerbations and loss of asthma control throughout pregnancy in women with asthma. Examination of the prevalence.

Change from baseline in (A) E-RS total score and (B) E-RS cough and sputum domain score over the study period in ATTAIN and the active-comparator study.

Body mass index (BMI) among subjects with normal spirometry, chronic obstructive pulmonary disease (COPD) and restrictive spirometry. Body mass index (BMI)

Effects of reslizumab on asthma control questionnaire-7 (ACQ-7) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of reslizumab.

A white elephant or the elephant in the room

Least squares (LS) mean change from baseline (95% CI) in St George's Respiratory Questionnaire (SGRQ) Total score according to chronic obstructive pulmonary.

An audit of the post-hospitalisation pulmonary rehabilitation pathway in a northwest London hospital. An audit of the post-hospitalisation pulmonary rehabilitation.

Roflumilast negli studi di Fase III: i dati di efficacia

Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to exacerbation history (intent-to-treat.

Use of medication among chronic obstructive pulmonary disease (COPD) cases by age and place of residence among 1586 COPD cases. The dark grey bar represents.

Systems biology as a tool to improve idiopathic pulmonary fibrosis (IPF) treatment effectiveness. Systems biology as a tool to improve idiopathic pulmonary.

a) Mortality per time point (p<0

Specific therapeutic and prophylactic interventions to consider in different taxonomic groups of chronic obstructive pulmonary diseases (COPDs). Specific.

Distribution of the differences in smallest worthwhile effects (SWEs) of land-based and water-based pulmonary rehabilitation on 6-min walk distance (in.

Prevalence of chronic obstructive pulmonary disease (COPD) defined by different criteria by age, and place of residence. The dark grey bar represents ‘rural’

Scatter plot of the % change versus baseline in pulmonary function test results at a) 4 months and b) the end of the study versus the analyte concentration.

3-year survival of lung cancer patients in the general population and in those with a prior diagnosis of chronic obstructive pulmonary disease (COPD).

Schematic overview of the suggested pharmacological management of chronic obstructive pulmonary disease (COPD). Schematic overview of the suggested pharmacological.

Benefit–risk balance and its individual determinants with personalised chronic obstructive pulmonary disease (COPD) treatment choices. Benefit–risk balance.

A family-based pulmonary rehabilitation (PR) programme enhanced the coping resources of the families of chronic obstructive pulmonary disease patients.

Changes in St. George's Respiratory Questionnaire (SGRQ) scores from baseline to 12 weeks for total samples (n=277), quitters (n=183) and continuous smokers.

Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to previous chronic obstructive pulmonary.

Forest plot meta-analysis of the impact of long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations on changes in.

SGRQ total scores by (A) FVC % predicted at baseline and (B) use of supplemental oxygen at baseline. SGRQ total scores by (A) FVC % predicted at baseline.

Worse eDiary scores are associated the more rescue inhaler usage and reduced step counts over both an individual day and 3-week summary period. Worse eDiary.

Comparison of total β2-agonist coverage for patients prescribed a) an increased dose of extrafine inhaled corticosteroids (ICS) versus ICS+long-acting.

Scatter plot of body mass index (BMI) versus forced expiratory volume in the first second (FEV1), and linear correlation lines for normal spirometry and.

Forest plot meta-analysis of the impact of long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations on a) St George's.

The effect of inhaled tiotropium (18 μg once daily) on the improvement in treadmill exercise endurance time in patients with chronic obstructive pulmonary.

Distribution of patients in the first- or second-year follow-up according to the number of acute exacerbations of chronic obstructive pulmonary disease.

Change in the regular use of inhaled corticosteroids (as a single inhaler or in combination; any use in the last 12 months) in participants with persistent.

Plots showing baseline correlation between the modified Medical Research Council (mMRC) dyspnoea scale, Baseline Dyspnoea Index (BDI), COPD Assessment.

Cardiac index (CI) changes from baseline following single oral doses of riociguat (○) 1 mg and 2.5 mg compared with inhaled nitric oxide (•) in patients.

Schematic diagram of the shared subgroups between asthma and chronic obstructive pulmonary disease (COPD). Schematic diagram of the shared subgroups between.

Forest plot from meta-analysis carried out on four studies including high-dose N-acetylcysteine (NAC) treatment a) assessing the relative risk of chronic.

Adjusted mean±se response in peak forced expiratory volume in 1 s within 3 h post-dosing (peak FEV10–3h) at week 24, following once-daily tiotropium Respimat.

Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification based on symptom and risk evaluation. a) GOLD model of symptom/risk evaluation.

Mean (95% CI) change in Clinical COPD Questionnaire (CCQ) with pulmonary rehabilitation, according to achievement (+) or non-achievement (−) of the established.

Scatterplots showing baseline correlation between forced expiratory volume in 1 s (FEV1) % pred and a) COPD Assessment Test (CAT), b) Clinical COPD Questionnaire.

Study designs for double-blind single maintenance and reliever therapy (SMART) studies. Study designs for double-blind single maintenance and reliever.

Choosing inhaler therapy for patients with stable COPD based on the Global Initiative for Chronic Obstructive Lung Disease grouping. Choosing inhaler therapy.

Effects of reslizumab on lung function (forced expiratory volume in 1 s; FEV1) in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of.

Comparison of exhaled H2O2 values in chronic obstructive pulmonary disease (COPD) patients (n=12) and control group (n=9). a) Raw ambient air concentrations.

Cardiac index (CI) changes from baseline following single oral doses of riociguat (Rio) compared with inhaled nitric oxide (NO) in patients with chronic.

Frequency distribution histograms of the Exacerbations of Chronic Pulmonary Disease Tool (EXACT) total, the COPD Assessment Test (CAT), the St George’s.

Receiver operating characteristic (ROC) curves for Saint George’s Respiratory Questionnaire (SGRQ) category scores predicting chronic obstructive pulmonary.

The natural history of chronic obstructive pulmonary disease (COPD) is a mixture of the natural history of the various phenotypes making up the umbrella.

Presentation transcript:

Least squares (LS) mean change from baseline (95% CI) in St George's Respiratory Questionnaire (SGRQ) Total score according to previous chronic obstructive pulmonary disease medication subgroups (intent-to-treat population). Least squares (LS) mean change from baseline (95% CI) in St George's Respiratory Questionnaire (SGRQ) Total score according to previous chronic obstructive pulmonary disease medication subgroups (intent-to-treat population). ICS: inhaled corticosteroid; LABA: long-acting β2-agonist; BUD: budesonide; FOR: formoterol; LAMA: long-acting muscarinic antagonist; TIO: tiotropium; FF/UMEC/VI: fluticasone furoate/umeclidinium/vilanterol (100/62.5/25 µg); BUD/FOR: budesonide/formoterol (400/12 µg). a) ICS+LABA, b) BUD+FOR, c) ICS+LABA+LAMA, d) LAMA alone, e) TIO alone and f) LAMA+LABA. The grey line indicates the 4-unit change in SGRQ score considered the minimal clinically important difference. David M.G. Halpin et al. ERJ Open Res 2018;4:00119-2017 ©2018 by European Respiratory Society